Author + information
- Received September 20, 2018
- Accepted October 4, 2018
- Published online January 28, 2019.
- Andrew Xanthopoulos, MD, PhDa,
- Randall C. Starling, MD, MPHa,
- Takeshi Kitai, MD, PhDb and
- Filippos Triposkiadis, MD, PhDc,∗ ()
- aDepartment of Cardiovascular Medicine, Heart and Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
- bDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
- cDepartment of Cardiology, Larissa University General Hospital, Larissa, Greece
- ↵∗Address for correspondence:
Dr. Filippos Triposkiadis, Department of Cardiology, Larissa University General Hospital, P.O. Box 1425, 411 10 Larissa, Greece.
Heart failure (HF) and liver disease often co-exist. This is because systemic disorders and diseases affect both organs (alcohol abuse, drugs, inflammation, autoimmunity, infections) and because of complex cardiohepatic interactions. The latter, which are the focus of this review, include the development of acute cardiogenic liver injury and congestive hepatopathy in HF as well as cardiac dysfunction and failure in the setting of liver cirrhosis, nonalcoholic fatty liver disease, and sequelae following liver transplantation. The emerging role of altered liver X receptor signaling in the pathogenesis of HF comorbidities as well as of the intestinal microbiome and its metabolites in HF and liver disease are fruitful areas for future research.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received September 20, 2018.
- Accepted October 4, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.